Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Exclusive-Head of Pemex's production arm to step down in coming days, sources say - 2Ancient mass grave discovered in water cistern during Tel Azekah excavations
- 3Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- 4Surprising links between autism, Alzheimer’s could change how we treat both
- 5Several killed in Ukraine and Russia after cross-border attacks
- 'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- Sound and Delightful: 12 Nutritious Smoothie Recipes
- Vote in favor of Your Number one BWM Vehicles
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- Moving Wedding Objections for Paramount Functions
- Merz: 80% of Syrians in Germany expected to return within three years
- The largest sun of 2026 rises today as Earth draws closest to our parent star
- From School Dropout to Example of overcoming adversity: My Excursion
- What are the health benefits of whole milk for kids?
